Published in Antimicrob Agents Chemother on January 01, 1994
In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother (1995) 1.60
Extrachromosomal DNA in the Apicomplexa. Microbiol Mol Biol Rev (1997) 1.60
Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest (1995) 1.45
Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother (1997) 1.41
A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob Agents Chemother (2003) 1.26
Localization of azithromycin in Toxoplasma gondii-infected cells. Antimicrob Agents Chemother (1994) 0.94
Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob Agents Chemother (1999) 0.87
Chemistry and biology of macrolide antiparasitic agents. J Med Chem (2011) 0.85
Evaluation of drug effects on Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR. Parasitol Res (2010) 0.81
Role of calcium signaling in the transcriptional regulation of the apicoplast genome of Plasmodium falciparum. Biomed Res Int (2014) 0.76
Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii. PLoS One (2015) 0.76
Origins of prokaryotes, eukaryotes, mitochondria, and chloroplasts. Science (1978) 6.56
Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res (1984) 3.94
Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression--a review. J Antimicrob Chemother (1985) 3.36
Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J Biol Chem (1983) 3.11
Toxoplasma gondii: isolation and preliminary characterization of temperature-sensitive mutants. Exp Parasitol (1976) 3.02
Biochemical and genetic studies on two different types of erythromycin resistant mutants of Escherichia coli with altered ribosomal proteins. Mol Gen Genet (1973) 2.59
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool (1977) 2.53
Clindamycin uptake by human neutrophils. J Infect Dis (1981) 2.49
Inhibition of growth of Toxoplasma gondii in cultured fibroblasts by human recombinant gamma interferon. Infect Immun (1984) 2.32
Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother (1974) 2.14
Generation of a restriction fragment length polymorphism linkage map for Toxoplasma gondii. Genetics (1992) 2.01
Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother (1987) 1.91
Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med (1987) 1.89
The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg (1973) 1.66
Have malaria parasites three genomes? Parasitol Today (1991) 1.61
Identification of a single base change in ribosomal RNA leading to erythromycin resistance. J Biol Chem (1992) 1.54
In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis (1991) 1.50
Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother (1992) 1.48
Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Antimicrob Agents Chemother (1991) 1.37
Clindamycin in a murine model of toxoplasmic encephalitis. Antimicrob Agents Chemother (1987) 1.28
Successful chemotherapy of transfusion babesiosis. Ann Intern Med (1982) 1.28
Quantitative studies of the mutagenesis of Toxoplasma gondii. J Parasitol (1979) 1.08
Electron microscope studies of reproducing and interkinetic Toxoplasma. J Protozool (1962) 1.00
Inhibition of Toxoplasma gondii protein synthesis by azithromycin. Antimicrob Agents Chemother (1993) 0.99
DNA circles with cruciforms from Isospora (Toxoplasma) gondii. Biochim Biophys Acta (1984) 0.97
Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis (1991) 0.95
Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity. Infect Immun (1989) 0.88
Clindamycin for the treatment of falciparum malaria in Sudan. Am J Trop Med Hyg (1985) 0.86
Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother (1992) 1.48
Toxoplasma gondii: characterization of a mutant resistant to 6-thioxanthine. Exp Parasitol (1994) 1.20
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. J Med Chem (1996) 1.07
Toxoplasma gondii: characterization of a mutant resistant to sulfonamides. Exp Parasitol (1992) 1.00
Effects of the photobleaching herbicide, acifluorfen-methyl, on protoporphyrinogen oxidation in barley organelles, soybean root mitochondria, soybean root nodules, and bacteria. Arch Biochem Biophys (1990) 0.91
Protoporphyrinogen oxidation, a step in heme synthesis in soybean root nodules and free-living rhizobia. J Bacteriol (1989) 0.87
Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate. J Parasitol (1993) 0.86
Characteristics of purified protoporphyrinogen oxidase from barley. Biochem Biophys Res Commun (1989) 0.85
Lipophilic antifolates as candidates against opportunistic infections. Adv Exp Med Biol (1993) 0.81